Metabolism-based cardiomyocytes production for regenerative therapy. (March 2023)

• Record Type: Journal Article
• Authors: Umei, Tomohiko C.; Tohyama, Shugo; Fukuda, Keiichi
• Is Part Of: Journal of molecular and cellular cardiology. Volume 176(2023)
• Page Start: 11
• Page End: 20
• Publication Date: 2023-03
• Subjects: Metabolism -- Pluripotent stem cell -- Cardiomyocyte -- Regenerative therapy; acetyl-CoA acetyl coenzyme A -- ACO2 aconitase 2 -- αKG α- ketoglutarate -- bFGF basic fibroblast growth factor -- CMs cardiomyocytes -- COUP-TF chicken ovalbumin upstream promoter transcription factor -- ERK extracellular signal-regulated kinase -- ESCs embryonic stem cells -- ETC electron transport chain -- FAO fatty acid oxidation -- FHF first heart field -- GSH reduced glutathione -- GSK3 glycogen synthase kinase 3 -- hESCs human embryonic stem cells -- HIF1α hypoxia-inducible factor 1 subunit alpha -- hPSCs human pluripotent stem cells -- hPSC-CMs human pluripotent stem cell-derived cardiomyocytes -- HT heart transplantation -- ICM inner cell mass -- IDH2/3 isocitrate dehydrogenase 2/3 -- IDO1 indoleamine 2, 3-dioxygenase 1 -- iPSCs induced pluripotent stem cells -- JMJD Jumonji domain-containing histone demethylase -- KYN kynurenine -- LIF leukemia inhibitory factor -- mEpiSCs mouse epiblast stem cells -- mESCs mouse embryonic stem cells -- mPSCs mouse pluripotent stem cells -- mTOR mammalian target of rapamycin -- MZT maternal to zygotic transition -- NAD nicotinamide adenine dinucleotide -- NADH reduced nicotinamide adenine dinucleotide -- NADPH reduced nicotinamide adenine dinucleotide phosphate -- OXPHOS oxidative phosphorylation -- PPAR peroxisome proliferator-associated receptor -- PSCs pluripotent stem cells -- PPP pentose phosphate pathway -- RA retinoic acids -- ROS reactive oxygen species -- SAM S-adenosyl methionine -- SCD1 stearoyl coenzyme A desaturase -- scRNA-seq single-cell RNA sequencing -- SHF second heart field -- STAT3 signal transducer and activator of transcription 3 -- TCA cycle tricarboxylic acid cycle -- TET ten-eleven translocation enzymes -- UCP2 uncoupling protein 2 -- ZGA zygotic genome activation; Cardiology -- Periodicals; Heart Diseases -- Periodicals; Molecular Biology -- Periodicals; Cardiologie -- Périodiques; Cardiology; Electronic journals; Periodicals; 616.12
• DOI: 10.1016/j.yjmcc.2023.01.007
• Languages: English
• ISSNs: 0022-2828

Abstract

Abstract: Human pluripotent stem cells (hPSCs) are currently used in clinical applications such as cardiac regenerative therapy, studying disease models, and drug screening for heart failure. Transplantation of hPSC-derived cardiomyocytes (hPSC-CMs) can be used as an alternative therapy for heart transplantation. In contrast to differentiated somatic cells, hPSCs possess unique metabolic programs to maintain pluripotency, and understanding their metabolic features can contribute to the development of technologies that can be useful for their clinical applications. The production of hPSC-CMs requires stepwise specification during embryonic development and metabolic regulation is crucial for proper embryonic development. These metabolic features have been applied to hPSC-CM production methods, such as mesoderm induction, specifications for cardiac progenitors, and their maturation. This review describes the metabolic programs in hPSCs and the metabolic regulation in hPSC-CM production for cardiac regenerative therapy. Highlights: hPSC-CMs are used in regenerative therapy, studying disease models, and drug screening Metabolic regulation is crucial for heart development and hPSC-CMs production Metabolism affects cell properties and promotes the maturation of hPSC-CMs